MCID: HPT022
MIFTS: 55

Hepatoblastoma

Categories: Rare diseases, Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Liver diseases

Aliases & Classifications for Hepatoblastoma

MalaCards integrated aliases for Hepatoblastoma:

Name: Hepatoblastoma 12 76 53 29 55 6 44 15 73
Hbl 12

Classifications:



External Ids:

Disease Ontology 12 DOID:687
ICD10 33 C22.2
MeSH 44 D018197
NCIt 50 C3728
SNOMED-CT 68 109843000 45024009
UMLS 73 C0206624

Summaries for Hepatoblastoma

NIH Rare Diseases : 53 Hepatoblastoma is a rare malignant (cancerous) tumor of the liver that usually occurs in the first 3 years of life. In early stages of the condition, there may be no concerning signs or symptoms. As the tumor gets larger, affected children may experience a painful, abdominal lump; swelling of the abdomen; unexplained weight loss; loss of appetite; and/or nausea and vomiting. The exact underlying cause of hepatoblastoma is poorly understood. Risk factors for the tumor include prematurity with a very low birth weight, early exposure to hepatitis B infection, biliary atresia, and several different genetic conditions (i.e. Beckwith-Wiedemann syndrome, familial adenomatous polyposis, Aicardi syndrome, Glycogen storage disease, and Simpson-Golabi-Behmel syndrome). Treatment varies based on the severity of the condition but may include a combination of surgery, watchful waiting, chemotherapy, and/or radiation therapy.

MalaCards based summary : Hepatoblastoma, also known as hbl, is related to familial adenomatous polyposis and beckwith-wiedemann syndrome, and has symptoms including icterus An important gene associated with Hepatoblastoma is APC (APC, WNT Signaling Pathway Regulator), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Endometrial cancer. The drugs Lenograstim and Nicotine have been mentioned in the context of this disorder. Affiliated tissues include liver, fetal liver and testes, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 Hepatoblastoma is an uncommon malignant liver cancer occurring in infants and children and composed of... more...

Related Diseases for Hepatoblastoma

Diseases related to Hepatoblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 190)
# Related Disease Score Top Affiliating Genes
1 familial adenomatous polyposis 31.2 APC CTNNB1 TP53
2 beckwith-wiedemann syndrome 31.0 AFP CDKN1C GPC3 H19 IGF2 TP53
3 simpson-golabi-behmel syndrome 30.7 CTNNB1 GPC3 IGF2
4 familial adenomatous polyposis 1 30.7 APC CTNNB1
5 embryonal sarcoma 30.4 CTNNB1 GPC3 TP53
6 teratoma 30.3 AFP KRT7 TP53
7 neuroblastoma 30.1 CASP3 CTNNB1 H19 IGF2 TP53
8 adenoma 30.1 APC CTNNB1 PLAG1 TP53
9 adenocarcinoma 29.9 APC BIRC5 CTNNB1 H19 TP53
10 hemihyperplasia, isolated 29.3 CDKN1C H19 IGF2
11 wilms tumor 5 29.1 CDKN1C CTNNB1 GPC3 H19 IGF2
12 hepatic adenomas, familial 29.0 AFP APC CTNNB1 GPC3 HNF1A
13 lung cancer susceptibility 3 28.1 APC CASP3 CTNNB1 H19 KRT7 TP53
14 hepatocellular carcinoma 27.7 AFP APC BIRC5 CASP3 CRNDE CTNNB1
15 cholangiocarcinoma 27.0 AFP CASP3 CTNNB1 GPC3 H19 HGF
16 breast cancer 26.6 APC BIRC5 CASP3 CRNDE CTNNB1 H19
17 mixed hepatoblastoma 12.1
18 macrotrabecular hepatoblastoma 11.9
19 hypobetalipoproteinemia, familial, 2 11.2
20 desmoid disease, hereditary 11.0 APC CTNNB1
21 adult hepatocellular carcinoma 10.9 CTNNB1 TP53
22 silver-russell syndrome due to an imprinting defect of 11p15 10.9 H19 IGF2
23 chylomicron retention disease 10.9
24 silver-russell syndrome due to 11p15 microduplication 10.9 H19 IGF2
25 beckwith-wiedemann syndrome due to imprinting defect of 11p15 10.9 H19 IGF2
26 meninges sarcoma 10.9 IGF2 TP53
27 short-rib thoracic dysplasia 4 with or without polydactyly 10.8 CASP3 TP53
28 intestinal benign neoplasm 10.8 APC CTNNB1 TP53
29 hyperplastic polyposis syndrome 10.8 APC TP53
30 testicular malignant germ cell cancer 10.8 AFP GPC3
31 atypical teratoid rhabdoid tumor 10.7 CTNNB1 IGF2 TP53
32 peutz-jeghers syndrome 10.7 APC CTNNB1 TP53
33 colorectal adenoma 10.7 APC CTNNB1 TP53
34 vulvar intraepithelial neoplasia 10.7 BIRC5 TP53
35 anaplastic thyroid cancer 10.7 CASP3 CTNNB1 TP53
36 ovarian embryonal carcinoma 10.7 AFP GPC3
37 female reproductive organ cancer 10.6 CASP3 CTNNB1 TP53
38 marek disease 10.6 H19 TP53
39 respiratory system cancer 10.6 CASP3 CTNNB1 TP53
40 testicular germ cell tumor 10.6 AFP GPC3 TP53
41 bladder transitional cell papilloma 10.6 BIRC5 TP53
42 intrahepatic bile duct adenoma 10.6 AFP KRT7
43 tongue squamous cell carcinoma 10.5 CASP3 CTNNB1 TP53
44 bladder benign neoplasm 10.5 IGF2 KRT7
45 malignant spiradenoma 10.5 KRT7 TP53
46 large intestine adenocarcinoma 10.5 CTNNB1 KRT7
47 female reproductive endometrioid cancer 10.4 CTNNB1 KRT7 TP53
48 lung acinar adenocarcinoma 10.4 CTNNB1 KRT7
49 signet ring cell adenocarcinoma 10.4 CTNNB1 KRT7 TP53
50 renal pelvis adenocarcinoma 10.4 AFP KRT7

Graphical network of the top 20 diseases related to Hepatoblastoma:



Diseases related to Hepatoblastoma

Symptoms & Phenotypes for Hepatoblastoma

UMLS symptoms related to Hepatoblastoma:


icterus

GenomeRNAi Phenotypes related to Hepatoblastoma according to GeneCards Suite gene sharing:

26 (show all 34)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.97 CTNNB1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.97 CTNNB1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.97 AFP
4 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.97 IGF2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.97 AFP
6 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.97 IGF2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.97 APC
8 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.97 KRT7
9 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.97 IGF2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.97 IGF2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.97 APC CTNNB1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.97 AFP APC KRT7
13 Increased shRNA abundance (Z-score > 2) GR00366-A-195 9.97 IGF2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.97 CTNNB1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.97 APC
16 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.97 AFP APC
17 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.97 CTNNB1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.97 APC CTNNB1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.97 IGF2 AFP
20 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.97 CTNNB1 IGF2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.97 CTNNB1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.97 APC IGF2 KRT7 CTNNB1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.97 IGF2 CTNNB1
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-112 9.83 HNF1A
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-14 9.83 HNF1A
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-212 9.83 HNF1A
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.83 HNF1A
28 Decreased shRNA abundance (Z-score < -2) GR00366-A-28 9.83 HNF1A
29 Decreased shRNA abundance (Z-score < -2) GR00366-A-38 9.83 HNF1A
30 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.83 KRT7
31 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.83 KRT7
32 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 9.83 HNF1A APC CDKN1C KRT7
33 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.83 HNF1A
34 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 9.83 CDKN1C KRT7

MGI Mouse Phenotypes related to Hepatoblastoma:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.29 APC CTNNB1 APOA1 BIRC5 CASP3 PPARA
2 cardiovascular system MP:0005385 10.22 CASP3 APC CDO1 CTNNB1 APOA1 PPARA
3 homeostasis/metabolism MP:0005376 10.22 AFP CASP3 APC CDO1 CTNNB1 APOA1
4 endocrine/exocrine gland MP:0005379 10.17 APC CDO1 CTNNB1 APOA1 BIRC5 CASP3
5 embryo MP:0005380 10.06 TP53 APC CTNNB1 BIRC5 IGF2 GPC3
6 craniofacial MP:0005382 10.04 CASP3 APC CDO1 CTNNB1 TP53 IGF2
7 digestive/alimentary MP:0005381 10.02 TP53 CASP3 APC CTNNB1 HNF1A IGF2
8 integument MP:0010771 10.02 CASP3 APC CTNNB1 APOA1 PPARA HNF1A
9 liver/biliary system MP:0005370 9.97 APC CTNNB1 APOA1 AFP PPARA HNF1A
10 no phenotypic analysis MP:0003012 9.8 TP53 CASP3 APC CTNNB1 HGF HNF1A
11 renal/urinary system MP:0005367 9.56 CASP3 APC CTNNB1 HNF1A TP53 IGF2
12 pigmentation MP:0001186 9.55 TP53 CASP3 APC CTNNB1 GPC3
13 reproductive system MP:0005389 9.32 AFP APC CDO1 CTNNB1 CASP3 HNF1A

Drugs & Therapeutics for Hepatoblastoma

Drugs for Hepatoblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 85)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4,Phase 1,Not Applicable 135968-09-1
2
Nicotine Approved Phase 4 54-11-5 942 89594
3 Adjuvants, Immunologic Phase 4,Phase 1,Not Applicable
4
Etoposide Approved Phase 3,Phase 1,Phase 2,Not Applicable 33419-42-0 36462
5
Cisplatin Approved Phase 3,Phase 2 15663-27-1 84093 441203 2767
6
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
7
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
8
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
9
Vincristine Approved, Investigational Phase 3,Phase 1 2068-78-2, 57-22-7 5978
10
Oxaliplatin Approved, Investigational Phase 3,Phase 2 61825-94-3 5310940 9887054 43805 6857599
11
Amifostine Approved, Investigational Phase 3,Phase 1 20537-88-6 2141
12
Fluorouracil Approved Phase 3 51-21-8 3385
13
Gemcitabine Approved Phase 3 95058-81-4 60750
14
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
15
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
16
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
17
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
18
Cyproheptadine Approved Phase 3 129-03-3 2913
19
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
20
Camptothecin Experimental Phase 3,Phase 2,Phase 1 7689-03-4
21
Doxil Approved June 1999 Phase 3,Phase 2 31703
22 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
23 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
24 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
25 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
26 Etoposide phosphate Phase 3,Phase 1,Phase 2,Not Applicable
27 Immunosuppressive Agents Phase 3,Phase 1,Phase 2,Not Applicable
28 Liver Extracts Phase 3,Phase 2,Phase 1
29 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
30 sodium thiosulfate Phase 3
31 Chelating Agents Phase 3
32 Antidotes Phase 3
33 Anti-Infective Agents Phase 3,Phase 2,Phase 1
34 Antioxidants Phase 3
35 Protective Agents Phase 3,Phase 1,Not Applicable
36 Radiation-Protective Agents Phase 3,Phase 1
37 Antitubercular Agents Phase 3
38 Antimetabolites Phase 3,Phase 1
39 Antimetabolites, Antineoplastic Phase 3
40 Antimitotic Agents Phase 3,Phase 1,Not Applicable
41 Antifungal Agents Phase 3,Phase 2,Phase 1
42 Protein Kinase Inhibitors Phase 3
43 Antiviral Agents Phase 3
44 Hematinics Phase 3
45
Histamine Phosphate Phase 3 51-74-1 65513
46 Serotonin Agents Phase 3
47 Serotonin Antagonists Phase 3
48 Gastrointestinal Agents Phase 3
49 Complement C3a Phase 3
50 Neurotransmitter Agents Phase 3

Interventional clinical trials:

(show all 46)
# Name Status NCT ID Phase Drugs
1 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Not yet recruiting NCT02933333 Phase 4
2 Combination Chemotherapy With or Without Amifostine in Treating Young Patients With Liver Cancer Completed NCT00003994 Phase 3 cisplatin;vincristine sulfate;fluorouracil;amifostine trihydrate;carboplatin
3 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed NCT00716976 Phase 3 sodium thiosulfate
4 Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, II, or III Childhood Liver Cancer Completed NCT00652132 Phase 3 cisplatin;sodium thiosulfate
5 Chemotherapy in Treating Children With Liver Cancer Completed NCT00003912 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride
6 Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery Recruiting NCT03533582 Phase 2, Phase 3 Carboplatin;Cisplatin;Doxorubicin;Etoposide;Fluorouracil;Gemcitabine;Irinotecan;Oxaliplatin;Sorafenib;Vincristine Sulfate
7 Paediatric Hepatic International Tumour Trial Recruiting NCT03017326 Phase 3 Cisplatin;Doxorubicin;Carboplatin;5Fluorouracil;Vincristine;Etoposide;Irinotecan;Gemcitabine;Oxaliplatin;Sorafenib
8 Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Suspended NCT00980460 Phase 3 Cisplatin;Doxorubicin Hydrochloride;Fluorouracil;Irinotecan Hydrochloride;Temsirolimus;Vincristine Sulfate
9 Study to Assess Safety and Efficacy of ELAD in Subjects With Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure Terminated NCT01829347 Phase 3
10 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
11 Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma Unknown status NCT00287976 Phase 2 irinotecan hydrochloride
12 Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma Unknown status NCT00077389 Phase 2 carboplatin;cisplatin;doxorubicin hydrochloride
13 Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors Unknown status NCT00179816 Phase 1, Phase 2 High-Dose Chemotherapy with Tandem PBSC Rescue.
14 A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB Completed NCT01125800 Phase 1, Phase 2 LDE225
15 Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01154816 Phase 2 Alisertib
16 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
17 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
18 Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors Completed NCT00024258 Phase 2 arsenic trioxide
19 Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors Recruiting NCT01956669 Phase 2 Pazopanib GW786034
20 Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Recruiting NCT02867592 Phase 2 Cabozantinib S-malate
21 Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Recruiting NCT03526250 Phase 2 Palbociclib
22 Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03220035 Phase 2 Vemurafenib
23 Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Recruiting NCT03233204 Phase 2 Olaparib
24 Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Recruiting NCT03213704 Phase 2 Larotrectinib
25 PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03213678 Phase 2 PI3K/mTOR Inhibitor LY3023414
26 Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03210714 Phase 2 Erdafitinib
27 Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib;Olaparib;Palbociclib;PI3K/mTOR Inhibitor LY3023414;Selumetinib Sulfate;Tazemetostat;Vemurafenib
28 A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors Recruiting NCT01804634 Phase 2 Cyclophosphamide;Fludarabine;Melphalan;Sirolimus
29 Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Suspended NCT03213665 Phase 2 Tazemetostat
30 Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors Withdrawn NCT02011126 Phase 2 imetelstat sodium
31 Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors Unknown status NCT00007813 Phase 1 carboplatin;cyclophosphamide;etoposide
32 Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors Recruiting NCT02390843 Phase 1 Simvastatin;Cyclophosphamide;Topotecan;Myeloid growth factor
33 A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy Recruiting NCT02085148 Phase 1 Regorafenib (BAY73-4506);Vincristine (Cellcristin®);Irinotecan (Irinotecan Cell pharm®)
34 Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors Active, not recruiting NCT01331135 Phase 1 sirolimus
35 Nab-paclitaxel in Combination With Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors Not yet recruiting NCT03507491 Phase 1 Gemcitabine;Nab-paclitaxel
36 Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors Terminated NCT00003926 Phase 1 amifostine trihydrate;busulfan;filgrastim;melphalan;thiotepa
37 MT2004-30: Tomotherapy for Solid Tumors Terminated NCT00623077 Phase 1 busulfan;etoposide;ifosfamide;melphalan;thiotepa;Mesna
38 Cancer and Hearing Loss Related in Children Unknown status NCT02425397
39 Biomarkers in Tissue Samples From Young Patients With Liver Cancer Completed NCT01336881
40 Gene Mutation in Samples From Young Patients With Pleuropulmonary Blastoma Syndrome at Risk for Developing Cancer Completed NCT01353300
41 Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer Completed NCT00002485
42 Combined Modality Therapy in Hepatoblastoma: South Egypt Cancer Institute Experience Recruiting NCT02557750
43 Auto Transplant for High Risk or Relapsed Solid or CNS Tumors Recruiting NCT01505569 Not Applicable Ifosfamide;Etoposide;Mesna;Busulfan;Melphalan;Thiotepa;Carboplatin;Paclitaxel;Anti-seizure prophylaxis;Ursodiol
44 Collecting and Storing Tissue From Young Patients With Cancer Recruiting NCT00898755
45 Hepatoblastoma Biology Study and Tissue Bank Withdrawn NCT00228683 Not Applicable
46 Early Enteral Tube Feedings in Children Receiving Chemo for AML/MDS & High Risk Solid Tumors Withdrawn NCT00624962 Not Applicable

Search NIH Clinical Center for Hepatoblastoma

Cochrane evidence based reviews: hepatoblastoma

Genetic Tests for Hepatoblastoma

Genetic tests related to Hepatoblastoma:

# Genetic test Affiliating Genes
1 Hepatoblastoma 29

Anatomical Context for Hepatoblastoma

MalaCards organs/tissues related to Hepatoblastoma:

41
Liver, Fetal Liver, Testes, Myeloid, Lung, Kidney, Brain

Publications for Hepatoblastoma

Articles related to Hepatoblastoma:

(show top 50) (show all 874)
# Title Authors Year
1
Prognostic and therapeutic factors influencing the clinical outcome of hepatoblastoma after liver transplantation: A single-institute experience. ( 29341393 )
2018
2
Two Cases of Hepatoblastoma in Young Adults. ( 29412770 )
2018
3
Long-term outcomes of liver transplantation for hepatoblastoma: A single-center 14-year experience. ( 29888545 )
2018
4
A novel tissue-based A9-catenin gene and immunohistochemical analysis to exclude familial adenomatous polyposis among children with hepatoblastoma tumors. ( 29446530 )
2018
5
Pediatric hepatoblastoma and hepatocellular carcinoma: lessons learned in the last decade. ( 29383417 )
2018
6
Oridonin increases anticancer effects of lentinan in HepG2 human hepatoblastoma cells. ( 29434900 )
2018
7
Pediatric patient with end-stage kidney disease secondary to Eagle-Barrett syndrome and metastatic unresectable hepatoblastoma treated successfully with chemotherapy and liver-kidney transplant. ( 29356335 )
2018
8
20(S)-Protopanaxadiol induces apoptosis in human hepatoblastoma HepG2 cells by downregulating the protein kinase B signaling pathway. ( 29434714 )
2018
9
Hepatoblastoma in a child with dextrocardia and possible histopathological alteration reminiscent of hepatocellular carcinoma after neoadjuvant chemotherapy. ( 29881566 )
2018
10
Hepatoblastoma: current understanding, recent advances, and controversies. ( 29375822 )
2018
11
Histological and immunohistochemical study of hepatoblastoma: correlation with tumour behaviour and survival. ( 29755772 )
2018
12
Comprehensive analysis and experimental verification of LINC01314 as a tumor suppressor in hepatoblastoma. ( 29571247 )
2018
13
Metastasectomy of Hepatoblastoma Utilizing a Novel Overlay Fluorescence Imaging System. ( 29906233 )
2018
14
Chrysotoxene induces apoptosis of human hepatoblastoma HepG2 cells <i>in vitro</i> and <i>in vivo</i> via activation of the mitochondria-mediated apoptotic signaling pathway. ( 29541233 )
2018
15
Single-walled carbon nanohorn aggregates promotes mitochondrial dysfunction-induced apoptosis in hepatoblastoma cells by targeting SIRT3. ( 29956732 )
2018
16
Expression Profiling Identifies Circular RNA Signature in Hepatoblastoma. ( 29414822 )
2018
17
Hepatoblastoma in a Child With Early-onset Cirrhosis. ( 29420370 )
2018
18
Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report. ( 29922990 )
2018
19
MicroRNA-17, MicroRNA-19b, MicroRNA-146a, MicroRNA-302d Expressions in Hepatoblastoma and Clinical Importance. ( 29889802 )
2018
20
Right trisegmentectomy after portal vein embolization in a high-risk toddler with hepatoblastoma. ( 29600326 )
2018
21
X-Linked Severe Combined Immunodeficiency and Hepatoblastoma: A Case Report and Review of Literature. ( 29620683 )
2018
22
Hepatocyte-Derived Lipocalin 2 Is a Potential Serum Biomarker Reflecting Tumor Burden in Hepatoblastoma. ( 29920228 )
2018
23
Therapeutic experience with hepatoblastoma associated with trisomy 18. ( 29701292 )
2018
24
Addition of Vincristine and Irinotecan to Standard Therapy in a Patient With Refractory High-risk Hepatoblastoma Achieving Long-term Relapse-free Survival. ( 29668545 )
2018
25
Hepatoblastoma in patients with molecularly proven familial adenomatous polyposis: Clinical characteristics and rationale for surveillance screening. ( 29719120 )
2018
26
Pretransplant trends in I+-fetoprotein levels as a predictor of recurrence after living donor liver transplantation for unresectable hepatoblastoma: A single-institution experience. ( 29761829 )
2018
27
Ginsenoside Rg1 impairs homologous recombination repair by targeting CtBP-interacting protein and sensitizes hepatoblastoma cells to DNA damage. ( 29952772 )
2018
28
Eluding liver transplantation in POSTTEXT III and IV Hepatoblastoma. ( 29906299 )
2018
29
18F-FDG PET/CT for Molecular Imaging of Hepatoblastoma in Beckwith-Wiedemann Syndrome. ( 29485435 )
2018
30
MiR-492 regulates metastatic properties of hepatoblastoma via CD44. ( 29314711 )
2018
31
Rapid decrease of serum alpha-fetoprotein and tumor volume predicts outcome in children with hepatoblastoma treated with neoadjuvant chemotherapy. ( 29744604 )
2018
32
Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma. ( 29854306 )
2018
33
Downregulation of transcription factor GATA4 sensitizes human hepatoblastoma cells to doxorubicin-induced apoptosis. ( 28349834 )
2017
34
Hepatoblastoma: Transplant Versus Resection Experience in a Latin American Transplant Center. ( 28620649 )
2017
35
Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups. ( 27775819 )
2017
36
Germline APC mutations in hepatoblastoma. ( 29251405 )
2017
37
Fine needle aspiration in the diagnosis and classification of hepatoblastoma: Analysis of 21 New Cases. ( 27933740 )
2017
38
Hepatoblastoma: A success report using a combination therapy with preoperative arterial embolization. ( 28473171 )
2017
39
Multidisciplinary management of hepatoblastoma in children: Experience from a developing country. ( 27781375 )
2017
40
Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration. ( 27884679 )
2017
41
Multimodality Treatment Outcome of Hepatoblastoma in a Resource Limited Country. ( 28588161 )
2017
42
Hepatoblastoma in an extremely low birth-weight infant with Beckwith-Wiedemann syndrome. ( 29203194 )
2017
43
Identification of differentially expressed genes, lncRNAs and miRNAs which are associated with tumor malignant phenotypes in hepatoblastoma patients. ( 29228631 )
2017
44
Systematic analysis of the molecular mechanism of microRNA-124 in hepatoblastoma cells. ( 29344147 )
2017
45
Fatal Central Nervous System Post-Transplant Lymphoproliferative Disease in a Patient Who Underwent Liver Transplantation for Hepatoblastoma. ( 28837514 )
2017
46
Prognostic roles of pathology markers immunoexpression and clinical parameters in Hepatoblastoma. ( 28851352 )
2017
47
A Challenging Case of Hepatoblastoma Concomitant with Autosomal Recessive Polycystic Kidney Disease and Caroli Syndrome-Review of the Literature. ( 28638817 )
2017
48
Molecular classification of hepatoblastoma and prognostic value of the HB 16-gene signature. ( 28510309 )
2017
49
A systematic surgical approach to hepatoblastoma with intracardiac extension. ( 28457172 )
2017
50
Genomic profiles of a hepatoblastoma from a patient with Beckwith-Wiedemann syndrome with uniparental disomy on chromosome 11p15 and germline mutation of APC and PALB2. ( 29190888 )
2017

Variations for Hepatoblastoma

ClinVar genetic disease variations for Hepatoblastoma:

6
(show all 11)
# Gene Variation Type Significance SNP ID Assembly Location
1 APC NM_000038.5(APC): c.4183A> T (p.Ser1395Cys) single nucleotide variant Pathogenic rs137854578 GRCh37 Chromosome 5, 112175474: 112175474
2 APC NM_000038.5(APC): c.4183A> T (p.Ser1395Cys) single nucleotide variant Pathogenic rs137854578 GRCh38 Chromosome 5, 112839777: 112839777
3 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
4 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
5 CTNNB1 NM_001904.3(CTNNB1): c.94G> T (p.Asp32Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs28931588 GRCh37 Chromosome 3, 41266097: 41266097
6 CTNNB1 NM_001904.3(CTNNB1): c.94G> T (p.Asp32Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs28931588 GRCh38 Chromosome 3, 41224606: 41224606
7 CTNNB1 NM_001904.3(CTNNB1): c.84_95delGTCTTACCTGGA (p.Gln28_Asp32delinsHis) deletion other GRCh38 Chromosome 3, 41224596: 41224607
8 MN1 NM_002430.2(MN1): c.927_929delGCA (p.Gln309del) deletion other rs747503495 GRCh37 Chromosome 22, 28195603: 28195605
9 MN1 NM_002430.2(MN1): c.927_929delGCA (p.Gln309del) deletion other rs747503495 GRCh38 Chromosome 22, 27799615: 27799617
10 ARID1A NM_006015.5(ARID1A): c.6259G> A (p.Gly2087Arg) single nucleotide variant other GRCh38 Chromosome 1, 26780157: 26780157
11 ARID1A NM_006015.5(ARID1A): c.6259G> A (p.Gly2087Arg) single nucleotide variant other GRCh37 Chromosome 1, 27106648: 27106648

Copy number variations for Hepatoblastoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 48501 11 1 52900000 Methylation H19 Hepatoblastoma
2 48504 11 1 52900000 Methylation IGF2 Hepatoblastoma

Expression for Hepatoblastoma

Search GEO for disease gene expression data for Hepatoblastoma.

Pathways for Hepatoblastoma

Pathways related to Hepatoblastoma according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.83 APC CASP3 CTNNB1 HGF IGF2 TP53
2
Show member pathways
12.72 APC BIRC5 CASP3 CTNNB1 TP53
3
Show member pathways
12.62 APC CTNNB1 HGF IGF2 TP53
4
Show member pathways
12.58 APC CASP3 CTNNB1 HGF TP53
5 12.42 APC BIRC5 CASP3 CTNNB1 HGF IGF2
6 11.98 AFP APC BIRC5 CTNNB1
7
Show member pathways
11.94 APC CTNNB1 GPC3 TP53
8 11.87 APC BIRC5 CASP3 CTNNB1 TP53
9 11.83 AFP APC HGF TP53
10
Show member pathways
11.76 APC BIRC5 CTNNB1 HNF1A TP53
11 11.67 APC CTNNB1 IGF2 TP53
12 11.61 BIRC5 CASP3 TP53
13 11.44 APC CASP3 TP53
14 11.4 CASP3 CTNNB1 GPC3 HGF IGF2 TP53
15 11.35 APC CTNNB1 HNF1A
16 11.3 AFP APOA1 HNF1A
17 11.02 APC CTNNB1 HGF
18 10.96 BIRC5 CASP3 HNF1A TP53

GO Terms for Hepatoblastoma

Cellular components related to Hepatoblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 beta-catenin destruction complex GO:0030877 8.96 APC CTNNB1
2 Wnt signalosome GO:1990909 8.62 APC CTNNB1

Biological processes related to Hepatoblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.83 BIRC5 CASP3 HGF IGF2 TP53
2 negative regulation of transcription, DNA-templated GO:0045892 9.77 BIRC5 CDKN1C CTNNB1 PPARA TP53
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.5 HGF IGF2 TP53
4 positive regulation of transcription by RNA polymerase II GO:0045944 9.5 CTNNB1 HGF HNF1A IGF2 PLAG1 PPARA
5 cellular protein metabolic process GO:0044267 9.46 AFP APOA1 GPC3 IGF2
6 response to glucose GO:0009749 9.43 CASP3 HNF1A IGF2
7 fatty acid transport GO:0015908 9.4 HNF1A PPARA
8 positive regulation of neuron apoptotic process GO:0043525 8.8 CASP3 CTNNB1 TP53

Molecular functions related to Hepatoblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.62 CASP3 CDKN1C

Sources for Hepatoblastoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....